CD38 and B-cell chronic lymphocytic leukemia: Selinexor did not alter the surface expression of CD38 on CLL cells (Fig. 5D) however the pre-treatment of CD38 + CLL cells with selinexor (500 nM) significantly (p < 0.001) increased NKG2A + NK cell degranulation in combination with daratumumab (Fig. 5E).